Compare GSK plc (GSK) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Illinois Tool Works Inc. — how do they compare? GSK plc trades at $52.33 (market cap $101.34B), while Illinois Tool Works Inc. trades at $279.09 (market cap $78.08B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | ITW | |
|---|---|---|
Market Cap | $101.34B | $78.08B |
Sector | Health | Industrials |
52-Week High | $61.18 | $299.60 |
52-Week Low | $36.20 | $241.07 |
Enterprise Value | $121.95B | $86.41B |
Dividend Yield | 3.49% | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Illinois Tool Works (ITW) trades at $272.28, up 0.29% on the day, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.66 surpassing expectations. ITW maintains strong profitability, with a net income margin of 19.32% and ROE of 96.88%, supported by solid cash flow from operations of $3.13B in 2025. Recent news highlights segment strength and a declared dividend of $1.61 per share for Q2 2026.
ITW presents a mixed outlook with robust fundamentals and technical strength offset by valuation concerns and modest growth. The consensus price target of $288.25 implies potential upside, but high P/E and P/B ratios suggest limited margin of safety. Risks include construction sector weakness and currency headwinds. Earnings on July 28, 2026, will be critical for confirming the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
